AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22124356 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionized compression tights
Number of subjects: 10
Study 22124356 — intervention group
Group type: COMPARATOR
Intervention: Standard running tights (control)
Number of subjects: 10
Study 19968890 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher tertile of EPA+DHA intake
Number of subjects: 644
Study 19968890 — intervention group
Group type: COMPARATOR
Intervention: Fish intake
Number of subjects: 644
Study 17415634 — intervention group
Group type: EXPERIMENTAL
Intervention: Da-Cheng-Qi-Tang (DCQT)
Number of subjects: 69
Study 15474696 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 47
Study 15474696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 11341416 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-12
Number of subjects: 3600
Study 11341416 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxford-12
Number of subjects: 3600
Study 11341416 — intervention group
Group type: COMPARATOR
Intervention: NHP, SF-12, SF-36, SIP, Lequesne, Oxford-12, WOMAC
Number of subjects: 3600
Study 9558127 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (VCM)
Number of subjects: 190
Study 8061901 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN‐gamma 1.8 mg
Number of subjects: 6
Study 8061901 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN‐gamma 0.2 mg and 0.6 mg
Number of subjects: 6
Study 8061901 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN‐gamma
Number of subjects: 6
Study 3421209 — intervention group
Group type: EXPERIMENTAL
Intervention: omega‐3 TG (triglyceride rich in omega‐3 FAs)
Number of subjects: 8
Study 3421209 — intervention group
Group type: EXPERIMENTAL
Intervention: omega‐3 ME (methyl esters)
Number of subjects: 8
Study 3421209 — intervention group
Group type: COMPARATOR
Intervention: control (18 vegetable-oil capsules)
Number of subjects: 8
Study 30068614 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Communication Education (ACE) programme plus hearing aid provision
Number of subjects: 84
Study 30068614 — intervention group
Group type: COMPARATOR
Intervention: Hearing aid provision alone
Number of subjects: 84
Study 27391922 — intervention group
Group type: EXPERIMENTAL
Intervention: Home enteral nutrition (HEN)
Number of subjects: 79
Study 27391922 — intervention group
Group type: COMPARATOR
Intervention: Nutritional counselling
Number of subjects: 79
Study 25907350 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaferon
Number of subjects: 90
Study 25907350 — intervention group
Group type: EXPERIMENTAL
Intervention: Avonex
Number of subjects: 90
Study 25907350 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebif
Number of subjects: 90
Study 23957526 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut-directed hypnotherapy (HYP), 7 sessions
Number of subjects: 54
Study 23957526 — intervention group
Group type: COMPARATOR
Intervention: Attention control (CON)
Number of subjects: 54
Study 23957526 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut-directed hypnotherapy (HYP)
Number of subjects: 54
Study 22212275 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Intensity (MI) resistance training (45‐55% 1RM)
Number of subjects: 30
Study 22212275 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity (HI) resistance training (80‐90% 1RM)
Number of subjects: 30
Study 22212275 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 30
Study 18362623 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar-coded sponge system
Number of subjects: 300
Study 18362623 — intervention group
Group type: COMPARATOR
Intervention: Traditional counting protocol
Number of subjects: 300
Study 17168363 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal radiotherapy (20‐24 Gy) in accelerated hyperfractionation (1.3‐1.5 Gy, twice a day, at 5‐hr interval)
Number of subjects: 117
Study 17168363 — intervention group
Group type: COMPARATOR
Intervention: Standard fractionation (38‐40 Gy)
Number of subjects: 117
Study 17168363 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal radiotherapy (20‐24 Gy) in accelerated hyperfractionation
Number of subjects: 117
Study 12584541 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (TG, n = 9) - individualized training on a cycle ergometer, exercising at an intensity set at the heart rate corresponding to the ventilatory threshold, with 1‐minute sprints against the maximal aerobic power (MAP) every 4 minutes, 45 minutes per session, 3 sessions per week
Number of subjects: 16
Study 12584541 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n = 7) - no specific intervention mentioned
Number of subjects: 16
Study 10588785 — intervention group
Group type: EXPERIMENTAL
Intervention: Dense spontaneous echocardiographic contrast (SEC)
Number of subjects: 772
Study 10588785 — intervention group
Group type: EXPERIMENTAL
Intervention: Any density of spontaneous echocardiographic contrast (SEC)
Number of subjects: 772
Study 10588785 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical, echocardiographic, and hemostatic parameters
Number of subjects: 772
Study 8733683 — intervention group
Group type: COMPARATOR
Intervention: 4 g/m2 cyclophosphamide (CY)
Number of subjects: 32
Study 8733683 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 g/m2 cyclophosphamide (CY)
Number of subjects: 32
Study 1929094 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin 0.3% one drop every three hours the night before and the morning of surgery (half‐day regimen)
Number of subjects: 15
Study 1929094 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin 0.3% one drop qid for three days (three‐day regimen)
Number of subjects: 15
Study 1929094 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine 5% preparation
Number of subjects: 15
Study 7075329 — intervention group
Group type: EXPERIMENTAL
Intervention: Father treatment
Number of subjects: 42
Study 7075329 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother treatment
Number of subjects: 42
Study 7075329 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study 7075329 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (both father and mother)
Number of subjects: 42
Study 31601449 — intervention group
Group type: COMPARATOR
Intervention: Total nuts (10+ g/day)
Number of subjects: 62573
Study 31601449 — intervention group
Group type: COMPARATOR
Intervention: Tree nuts, peanuts, peanut butter
Number of subjects: 62573
Study 30672303 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity laser therapy + exercise therapy
Number of subjects: 46
Study 30672303 — intervention group
Group type: COMPARATOR
Intervention: Sham-laser + exercise therapy
Number of subjects: 46
Study 27624151 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 36
Study 27624151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 26498439 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton radiation therapy (PRT)
Number of subjects: 20
Study 24368307 — intervention group
Group type: EXPERIMENTAL
Intervention: CNTF‐3 low-dose implant
Number of subjects: 8
Study 24368307 — intervention group
Group type: EXPERIMENTAL
Intervention: CNTF‐3 high-dose implant
Number of subjects: 8
Study 24368307 — intervention group
Group type: EXPERIMENTAL
Intervention: CNTF‐4 high-dose implant
Number of subjects: 8
Study 22608696 — intervention group
Group type: EXPERIMENTAL
Intervention: P3P intervention
Number of subjects: 494
Study 22608696 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 494
Study 18974967 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg
Number of subjects: 49
Study 18974967 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 40 mg
Number of subjects: 49
Study 18974967 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 60 mg
Number of subjects: 49
Study 17300401 — intervention group
Group type: EXPERIMENTAL
Intervention: EXPORT catheter
Number of subjects: 129
Study 17300401 — intervention group
Group type: COMPARATOR
Intervention: Stent implantation
Number of subjects: 129
Study 14725952 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg propoxyphene napsylate
Number of subjects: 18
Study 14725952 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg propoxyphene napsylate
Number of subjects: 18
Study 14725952 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg propoxyphene napsylate
Number of subjects: 18
Study 14725952 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg morphine sulfate
Number of subjects: 18
Study 14725952 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg lorazepam
Number of subjects: 18
Study 14725952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11577993 — intervention group
Group type: EXPERIMENTAL
Intervention: (1‐‐>3)‐beta‐D‐glucan inhalation
Number of subjects: 21
Study 11577993 — intervention group
Group type: COMPARATOR
Intervention: Saline inhalation
Number of subjects: 21
Study 11360607 — intervention group
Group type: COMPARATOR
Intervention: 25 mg mifepristone
Number of subjects: 2387
Study 11360607 — intervention group
Group type: COMPARATOR
Intervention: 25 mg mifepristone plus 7.5 mg anordrin
Number of subjects: 2387
Study 11360607 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg mifepristone plus 5 mg anordrin
Number of subjects: 2387
Study 11360607 — intervention group
Group type: COMPARATOR
Intervention: 10 mg mifepristone
Number of subjects: 2387
Study 7472907 — intervention group
Group type: EXPERIMENTAL
Intervention: LBWI formula with LCP (n = 9)
Number of subjects: 27
Study 7472907 — intervention group
Group type: EXPERIMENTAL
Intervention: LBWI formula without LCP (n = 10)
Number of subjects: 27
Study 7472907 — intervention group
Group type: COMPARATOR
Intervention: Mother's milk fortified with protein and minerals (n = 8)
Number of subjects: 27
Study 2278323 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.3 mg/kg, continuous infusion, with nitrous oxide in oxygen
Number of subjects: 30
Study 2278323 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.3 mg/kg, continuous infusion, with nitrous oxide in oxygen (600 ng/litre)
Number of subjects: 30
Study 2278323 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.3 mg/kg, continuous infusion, with oxygen in air (600 ng/litre)
Number of subjects: 30
Study 2278323 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide in combination with midazolam
Number of subjects: 30
Study 7374550 — intervention group
Group type: EXPERIMENTAL
Intervention: Identical diffuse immunoblastic lymphoma
Number of subjects: 2
Study 28987525 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (320/1,600 mg twice daily for 7 days)
Number of subjects: 1057
Study 28987525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1057
Study 27465353 — intervention group
Group type: EXPERIMENTAL
Intervention: IC adrenaline ± verapamil through a well-cannulated guiding catheter
Number of subjects: 40
Study 27465353 — intervention group
Group type: COMPARATOR
Intervention: Local injection of adrenaline ± verapamil in the distal coronary bed through a perfusion balloon or selective microcatheter
Number of subjects: 40
Study 27465353 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 24105084 — intervention group
Group type: EXPERIMENTAL
Intervention: Embrace device treatment
Number of subjects: 12
Study 24105084 — intervention group
Group type: COMPARATOR
Intervention: Control (self-control)
Number of subjects: 12
Study 22447494 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL-16 levels in NP patients
Number of subjects: 27
Study 22447494 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nasal polyposis)
Number of subjects: 27
Study 22447494 — intervention group
Group type: COMPARATOR
Intervention: Comparison of serum IL-16 levels
Number of subjects: 27
Study 20470337 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol LCT premixed with lignocaine (0.1%)
Number of subjects: 80
Study 20470337 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol MCT/LCT premixed with lignocaine (0.1%)
Number of subjects: 80
Study 18188105 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ethanol infusion (EtOH)
Number of subjects: 50
Study 18188105 — intervention group
Group type: COMPARATOR
Intervention: Scheduled-dose diazepam (BENZO)
Number of subjects: 50
Study 15919488 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 557
Study 15919488 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 557
Study 12699021 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training (PT)
Number of subjects: 208
Study 12699021 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent and teacher training (PT + TT)
Number of subjects: 208
Study 12699021 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental conditions (PT and PT + TT)
Number of subjects: 208
Study 12699021 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control (C)
Number of subjects: 208
Study 12699021 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher training (TT)
Number of subjects: 208
Study 11086638 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin infusion for at least 5 days
Number of subjects: 1221
Study 11086638 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 1221
Study 8781002 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio feedback through the use of audiotaped role plays
Number of subjects: 0
Study 8781002 — intervention group
Group type: EXPERIMENTAL
Intervention: Role plays with peer feedback
Number of subjects: 0
Study 8781002 — intervention group
Group type: EXPERIMENTAL
Intervention: Video feedback
Number of subjects: 0
Study 8781002 — intervention group
Group type: COMPARATOR
Intervention: Traditional didactic lecture mode
Number of subjects: 0
Study 1468246 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sulodexide (2 capsules of 250 lipoproteinolipase releasing units twice daily)
Number of subjects: 36
Study 1468246 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 identical capsules twice daily)
Number of subjects: 36
Study 6475654 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide with potassium supplements (48 mmol/day)
Number of subjects: 9
Study 6475654 — intervention group
Group type: COMPARATOR
Intervention: Frusemide alone
Number of subjects: 9
Study 6475654 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium-sparing diuretic
Number of subjects: 9
Study 3097108 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind food challenge with lyophilized food in capsules or food mixed in broth
Number of subjects: 300
Study 3097108 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (300 mg 30 minutes before food challenge)
Number of subjects: 300
Study 3097108 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 300
Study 31023398 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (three commonly prescribed antidepressants)
Number of subjects: 1008
Study 30392345 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN) combined with parenteral nutrition (PN)
Number of subjects: 379
Study 30392345 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 379
Study 30392345 — intervention group
Group type: EXPERIMENTAL
Intervention: EEN+ PN in centrally located HCC (cl-HCC)
Number of subjects: 379
Study 30392345 — intervention group
Group type: COMPARATOR
Intervention: TPN in centrally located HCC (cl-HCC)
Number of subjects: 379
Study 30392345 — intervention group
Group type: EXPERIMENTAL
Intervention: EEN+ PN in non-centrally located HCC (ncl-HCC)
Number of subjects: 379
Study 30392345 — intervention group
Group type: COMPARATOR
Intervention: TPN in non-centrally located HCC (ncl-HCC)
Number of subjects: 379
Study 26337132 — intervention group
Group type: EXPERIMENTAL
Intervention: Categories of eGFR (estimated glomerular filtration rates)
Number of subjects: 19411
Study 23382580 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity computerized working memory training in school setting
Number of subjects: 0
Study 23382580 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 22425474 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment based on cognitive behavior therapy for 4 weeks
Number of subjects: 16
Study 22425474 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 females)
Number of subjects: 16
Study 20379679 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX ARC cement with ZO‐eugenol (ZOE)‐based cement (Group IV)
Number of subjects: 40
Study 20379679 — intervention group
Group type: COMPARATOR
Intervention: RelyX Unicem cement with ZO‐eugenol (ZOE)‐based cement (Group VIII)
Number of subjects: 40
Study 20379679 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX ARC cement with Ca(OH)2‐based cement (Group II)
Number of subjects: 40
Study 20379679 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX ARC cement with zinc oxide (ZO)‐based cement (Group III)
Number of subjects: 40
Study 20379679 — intervention group
Group type: COMPARATOR
Intervention: RelyX Unicem cement with Ca(OH)2‐based cement (Group VI)
Number of subjects: 40
Study 20379679 — intervention group
Group type: COMPARATOR
Intervention: RelyX Unicem cement with zinc oxide (ZO)‐based cement (Group VII)
Number of subjects: 40
Study 20379679 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX ARC cement with no temporary cementation (Group I)
Number of subjects: 40
Study 20379679 — intervention group
Group type: COMPARATOR
Intervention: RelyX Unicem cement with no temporary cementation (Group V)
Number of subjects: 40
Study 18355634 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong-alpha 3 sub-group (high band power)
Number of subjects: 10
Study 18355634 — intervention group
Group type: COMPARATOR
Intervention: Weak-alpha 3 sub-group (low band power)
Number of subjects: 10
Study 15778428 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg/week subcutaneous efalizumab for 12 weeks
Number of subjects: 1088
Study 15778428 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg/week subcutaneous efalizumab for 12 weeks
Number of subjects: 1088
Study 12686232 — intervention group
Group type: EXPERIMENTAL
Intervention: LASEK
Number of subjects: 92
Study 12686232 — intervention group
Group type: COMPARATOR
Intervention: PRK
Number of subjects: 92
Study 10898434 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen Uptake Efficiency Slope (OUES) calculated from the first 75% of the exercise test
Number of subjects: 1010
Study 10898434 — intervention group
Group type: EXPERIMENTAL
Intervention: OUES
Number of subjects: 1010
Study 10898434 — intervention group
Group type: EXPERIMENTAL
Intervention: OUES in congestive heart failure patients
Number of subjects: 1010
Study 8858790 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 0
Study 8858790 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound
Number of subjects: 0
Study 1332463 — intervention group
Group type: EXPERIMENTAL
Intervention: Guava fruit intake (group A)
Number of subjects: 120
Study 1332463 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 120
Study 3968617 — intervention group
Group type: EXPERIMENTAL
Intervention: SMA Gold Cap (Group A)
Number of subjects: 74
Study 3968617 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary calcium to 21 mmol/L (Group B)
Number of subjects: 74
Study 3968617 — intervention group
Group type: EXPERIMENTAL
Intervention: Further calcium supplementation to 31.2 mmol/L (Group C)
Number of subjects: 74
Study 3968617 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk with calcium content 31.2 mmol/L and phosphorus supplementation to 15.7 mmol/L (Group D)
Number of subjects: 74
Study 29489730 — intervention group
Group type: EXPERIMENTAL
Intervention: Bounce technique
Number of subjects: 20
Study 29489730 — intervention group
Group type: COMPARATOR
Intervention: Pause technique
Number of subjects: 20
Study 25416755 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week NRT supply
Number of subjects: 1495
Study 25416755 — intervention group
Group type: COMPARATOR
Intervention: 8-week NRT supply (split-shipment protocol)
Number of subjects: 1495
Study 24852701 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg 1 hour before sexual intercourse
Number of subjects: 82
Study 24852701 — intervention group
Group type: COMPARATOR
Intervention: Nasal CPAP during night time sleep
Number of subjects: 82
Study 21380565 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic normothermia group with target core temperature 36.5°C using endovascular cooling
Number of subjects: 63
Study 21380565 — intervention group
Group type: COMPARATOR
Intervention: Conventional temperature management using antipyretic medication and surface cooling (active control group)
Number of subjects: 63
Study 21380565 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (endovascular and conventional)
Number of subjects: 63
Study 21380565 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular group with NSAIDs
Number of subjects: 63
Study 20212256 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence Score (RS) in N0 patients
Number of subjects: 1231
Study 20212256 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence Score (RS) in N+ patients
Number of subjects: 1231
Study 20212256 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence Score (RS) in both N0 and N+ patients
Number of subjects: 1231
Study 17545052 — intervention group
Group type: EXPERIMENTAL
Intervention: Huafenqinutang combined with vardenafil for 8 weeks (vardenafil added from week 5)
Number of subjects: 138
Study 17545052 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with Huafenqinutang for 8 weeks
Number of subjects: 138
Study 16353044 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day, n=20)
Number of subjects: 38
Study 16353044 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day, n=18)
Number of subjects: 38
Study 12168367 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 117
Study 12168367 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 117
Study 12168367 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 117
Study 14564602 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2% isoflurane
Number of subjects: 12